Potential RA Therapy, CT-P10, Seen in Study to Be Biosimilar to Rituxan
News
In a Phase 1 clinical trial, researchers showed that CT-P10 is a biosimilar to Rituxan (rituximab), a current treatment of choice for rheumatoid arthritis (RA) patients who fail to respond to ... Read more